Odonate Therapeutics Inc. made misleading statements about the safety or tolerance of its new chemotherapy drug, overstating its commercial viability as a cancer treatment, investors say in a securities class action complaint filed in a California federal court.
The complaint centers on Tesetaxel, which is in a Phase 3 clinical study for patients with locally advanced or metastatic breast cancer. The trial is studying tesetaxel in combination with the chemotherapy capecitabine.
The class period started in December 2017, when Odonate began publicly trading after submitting a registration statement that said tesetaxel was “generally well tolerated in clinical studies,” according to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.